Trial
NCT04601467
PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National University Heart Centre, Singapore
Collaborators
AstraZeneca; University of Otago
Condition
Acute Coronary Syndrome
Intervention
AZD5718
Why stopped
The study was terminated early on 14th September 2023 by the main funding company because of financial futility. We were able to enroll 243 of the initial planned 360 participants and randomised 209 participants of the intial planned 286.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-27